Potential drug-drug interactions among patients with chronic kidney disease admitted at National Hospital: a retrospective study in Tanzania

CURRENT STATUS: UNDER REVIEW

BMC Nephrology ▶ BMC Series

Wigilya Mikomangwa ️ wpad.miko@gmail.com
Muhimbili University of Health and Allied Sciences
Corresponding Author
ORCiD: 0000-0002-6385-878X

Jephter E. Malifa
Muhimbili University of Health and Allied Sciences

Hamu Mlyuka
Muhimbili University of Health and Allied Sciences

Ritah Mutagonda
Muhimbili University of Health and Allied Sciences

Manase Kilonzi
Muhimbili University of Health and Allied Sciences

Wema Kibanga
Muhimbili University of Health and Allied Sciences

Alphonce Ignace Marealle
Muhimbili University of Health and Allied Sciences

George Msema Bwire
Muhimbili University of Health and Allied Sciences

DOI:
10.21203/rs.2.21799/v1

SUBJECT AREAS
Urology & Nephrology

KEYWORDS
Chronic kidney disease, polypharmacy, potential drug-drug interaction
Abstract

Background: Drug related problems such as drug-drug interactions (DDI) are likely to occur in chronic kidney disease (CKD) patients due to polypharmacy practice. The DDI increases the risk of morbidity, mortality, prolonged hospital and cost of treatment. In most cases, the potential drug-drug interactions (pDDI) are not checked during prescribing or dispensing of polypharmacy for CKD patients in developing countries like Tanzania. Therefore, we documented the pattern and potential drug-drug interactions (DDIs) among CKD patients admitted at Muhimbili National Hospital (MNH).

Methods: The study retrospectively reviewed 198 files for CKD patients admitted at MNH between January 2017 and December 2018. The social-demographic characteristics and comorbidities were documented using a checklist. Prescriptions with polypharmacy were reviewed and prescribed medicines were documented. Medscape drug interaction checker was used for pDDIs. The SPSS version 23.0 was used to carry out statistical analysis.

Results: The study involved a total of 306 prescriptions with polypharmacy with a mean(±SD) of 6.21(±1.22) medicines per prescription. Majority of patients (77.2%) were in stage 5 of chronic kidney disease. Frequently prescribed medicines were pantoprazole 135(44.1%), furosemide 133(43.5%), ferrotone 101(33.0%), calcium carbonate 91(29.7%), amlodipine 121(39.5%), nifedipine 83(27.1%), bisoprolol 46(15.0%) and clonidine 38(12.4). The prevalence of pDDIs was 94.1%. The total of 1743 potential drug-drug interactions was observed with a mean of 6.03(±2.12) interactions per prescription. Majority of the pDDIs were moderate (67.5%) whereas, 29.5%, 2.6% and 0.3 were minor, serious and contraindicated respectively. The occurrence of pDDIs was associated with stroke (P-value=0.038), diabetes mellitus (p-value=0.049) and hypertension with diabetes mellitus (p-value=0.047).

Conclusion: The prevalence of pDDIs was high among the CKD patients. The determinants
of pDDIs among CKD patients were hypertension, diabetes mellitus and stroke. Interaction checkers should be incorporated in health system to guide the prescribing and dispensing of medicine for CKD patients.

**Background**

Chronic kidney disease (CKD) is among the leading course of morbidity and mortality worldwide (1,2). The global prevalence of CKD ranges between 11% and 13% while the prevalence of CKD in Tanzania was 13.6% (3,4). The mortality attributed to CKD has been increasing from time to time, for example, there was an increase of 32% of mortality in ten years from 2005 to 2015 (5). It has been estimated that, about 10 million people die from kidney disease each year (2,3). Lack of access to proper management of CKD has been reported to be a challenge due to expenses, making the condition worse in developing countries like Tanzania (2). In 2010, about 7 million patients with end stage kidney disease (ESKD) died due to lack of access to dialysis (2).

The CKD is accompanied with other diseases such as cardiovascular (hypertension, heart failure and stroke) and diabetes mellitus (1,3,4,6). Therefore, prescriptions with more than one medicine for treatment of these patients is a common practice. An average of 6–8 medicines have been reported to be prescribed to CKD patients (7-10). When the prescription contains five or more medicines is referred to as polypharmacy (11). In developing countries the prevalence of polypharmacy is above 80% (9-11). The risk of pDDIs rises to 40.0% among patients taking five drugs and 80.0% in patients with more than five drugs (12). The prevalence of pDDIs among patients receiving polypharmacy has been reported to be between 59–89.1% (9). The pDDIs predispose CKD patients into severe morbidity, increased mortality rate, high treatment cost and prolonged hospital stay (10). The severity of these interactions may be affected by the renal status of the patients. The mild interaction experienced by renal competent patients may be life
threatening in patients with impaired renal disease since their pharmacokinetic responses to the drugs are altered (6).

Despite the inevitable polypharmacy practice among CKD patients there is still a critical need to minimize the number of prescribed medicines for these patients in order to reduce risk of associated outcomes (10). As there is an increasing prevalence of kidney diseases in developing countries (1,4) and the ongoing improvement of nephrology services in Tanzania, the need of studies on the pattern and potential of DDIs is important in order to closely monitor the prescribed medicines among CKD patients. However, to our understanding there are no sufficient published evidence on the pattern and pDDIs among CKD patients admitted at MNH.

Methods

Study design and setting

This was a retrospective study that was conducted to CKD patients admitted at nephrology unit, MNH. MNH is a National Referral Hospital, Research Center and University Teaching Hospital, which admits 1,000 to 1,200 patients per week. The MNH has well established nephrology department, in which it offers specialized medical and dialysis services to CKD patients. In recent years, MNH have been performing successfully renal transplants to patients with ESKD. The study was conducted from November 2018 to July 2019 involving CKD patients admitted between January, 2017 and December, 2018.

Sampling and data collection

The study involved consecutive medical files of CKD patients admitted in nephrology unit at MNH. Considering the 80% prevalence of pDDIs among CKD patients and 6% margin of error, the minimum of 198 files were included in the study (12,13). All prescriptions that were present in the medical file were evaluated for pDDIs. Prescriptions that had less than five medicines or incomplete were excluded from the study.
Socio-demographic characteristics and clinical information such as age, sex, marital status, education level, occupation, history of smoking, alcohol consumption, comorbidities and stage of CKD were recorded from patient file. The prescribed medicines were recorded from the prescription by their generic names.

Assessment of pDDIs

The pDDIs were assessed using Medscape interaction checker, WebMD LLC. This is an online software program that provided the four categories of pDDIs; minor, moderate, serious and contraindicated. The software allows checking interactions between two drugs. Since we included prescriptions with at least five drugs, various combination of drugs on each prescription were checked. As per the Medscape interaction checker software, “minor interaction” meant the significance of interaction was not known, “moderate interactions” required the physician to monitor the patient closely (use the combination with caution) while “serious interaction” required to use alternative/monitor closely, the contraindicated interaction was to avoid concomitant administration of drugs.

Data analysis

Descriptive statistics were done, and frequency distribution table and graphs were used to summarize the results in Microsoft Excel, cleaned and analyzed by SPSS (statistical package for social sciences) version 23.0 software. Chi-Square and Fischer Exact tests were used for analysis of categorical variables. To describe the prevalence of pDDIs, we calculated the percentages of pDDIs by patient. Categorical variables with a p-value of < 0.2 were subjected to logistic regression models to identify factors associated with pDDIs. The p-value < 0.05 at 95% Confidence interval was deemed significant.

Results

Social demographic information
In total, 198 patient files of CKD patients were studied (table 1). Majority (59.1%) were female aged between 51–61 years old (38.4%) with a mean (± SD) of 52.82 (± 15.59) years. More than half of the patients (66.7%) were married. More than 50.0% of the patients were alcohol takers and only few (11.1%) had a history of smoking. Most of the patients’ information on occupation (86.4%) and education level (84.3%) were missing.

Medical condition and chronic kidney disease stage

The majority (72%) of CKD patients were under conservative care while 28% were on maintenance dialysis (Fig. 1) and no any patient was found under renal transplant. Hypertension and diabetes were present in 90.4% and 31.3% patients respectively, with 30.8% having both hypertension and diabetes. Most of them 77.2% were in stage-5 of CKD, followed by stage-4 (15.7%) and stage-3 (6.6%) and no patient had stage one (table2).

Prescribed medications and potential drug-drug interactions

Overall, 306 prescriptions with polypharmacy were obtained from 198 patient files with a mean (± SD) number 1.55(± 1.147) prescriptions per patient. In total, 1900 medicines were prescribed with mean (± SD) of 6.21(± 1.22) medicines per prescription. Frequently prescribed medicines were pantoprazole (44.1%), furosemide (43.5%), amlodipine (39.5%), ferrotone (33.0%), calcium carbonate (29.7%), nifedipine (27.1%), bisoprolol (15.0%) and clonidine (12.4).

The prevalence of pDDIs among CKD patients was 92.4%. Total of 1743 potential drug-drug interactions were observed with a mean (± SD) of 6.03 ± 2.12 interactions per prescription. Majority of the pDDIs were moderate interactions (67.5%). The minor, serious and contraindicated were 29.5%, 2.6% and 0.3% respectively.

The most common interactions observed were between furosemide and calcium carbonate (3.1%), pantoprazole and ferrotone (2.9%), bisoprolol and furosemide (1.8%) and clonidine
and metoprolol (0.8%) (Table 3). Other interactions observed were between ciprofloxacin and ondansetron (serious), metronidazole and tolvaptan (serious), hydralazine and bisoprolol (moderate) and clonidine and atenolol (serious).

On logistic regression analysis, CKD patients who had stroke were at 2-fold risk of experiencing pDDIs compared with those who had no stroke (aOR, 2.09; 95% CI, 1.78–36.76; p = 0.007). The pDDIs were high among CKD patients with diabetes mellitus (aOR, 1.17; 95% CI, 1.09–9.96; p = 0.04) and when hypertension occurred co-currently with diabetes (aOR, 1.19; 95% CI, 1.09–9.96; p < 0.03). Other comorbidities such as HIV infection and heart failure were not significantly associated with pDDIs.

Discussion

This study retrospectively assessed the prevalence and pattern of pDDIs among CKD patients admitted at MNH in Tanzania. The prevalence of pDDIs was 92.4%, and most of the pDDIs were moderate and minor interactions. This was much higher than a Pakistan study(12) that reported incidence of 78.5%. The lower pDDI rate in Pakistan study could have been due to the use of Micromedex Drug-Reax® system, unlike our study that used Medscape drug interaction checker to screen the drug-drug interaction profiles. A study done on comparison of drug-drug interaction software programs had shown differences regarding accuracy and comprehensiveness between the programs with disagreement in the severity of the interactions(16). Although variations exist in study designs of previous study, a high prevalence of pDDIs has been observed in CKD patients, which supports our study findings.

The high prevalence of stage 5 patients could be because the early stages 1–3 of CKD are usually asymptomatic thereby making the patients present at health facilities with CKD at advanced stages. Also the study was conducted at the National referral hospital which receives most of patients in their late stages from the countryside. Most of these patients
were on conservative care since most of CKD patients could not afford dialysis. 

We found that, a mean (± SD) of 6 ± 1.29 medicines per prescription which is lower than a study in Nigeria(10) which reported a mean (± SD) of 10.06 (± 3.97) medications. The number of medications in this study was close to a Palestine study(15) which reported a mean of 7.87 (± 2.44) medicines. This demonstrated how common polypharmacy is among CKD patients. The mostly prescribed medicines were useful in improving the quality of life of CKD patients. Among commonly prescribed medications in the study were calcium carbonate and furosemide similar to other studies (10,12,15). CKD patients at stage 3 to 5 are associated with cardiovascular events with edema, anemia and bone resorption which could have attributed to diuretics, beta-blockers, calcium channel blockers, ferrotone and calcium carbonate being prescribed (4,6).

Patients who had hypertension with diabetes, diabetes and stroke had increased risk of pDDIs. Since drugs were used in the treatment of CKD and comorbidities, concomitant administration of these drugs increased the risk of pDDIs. The drug-related problems could worsen the CKD and comorbidities (17). Therefore, care should be take when prescribing drugs to CKD patients with these comorbidities and pharmacist should be full involved in order to advice appropriately in reducing the number of medications (9,18).

Study limitation

Our study used Medscape interaction checker software program which was free and easily accessible in our settings. The software allowed only two drugs to be checked. Some interactions are dose dependent; the software did not have the option to check interactions related to doses. The software program did not take into account the time interval between drug administration; it assumes tow drugs are taken at the same time. In addition, there is no ideal software program for checking pDDIs. The outcome of interaction and the approach taken by the health care provider in case of adverse drug
reaction associated with pDDIs was not documented.

Conclusion

The prevalence of pDDIs was high among the CKD patients. The most common pDDIs were moderate and minor interactions and required close monitoring. Stroke, diabetes and hypertension with diabetes increased the chances of pDDIs, thus, health care providers need to pay special attention when attending patients with these commodities. Electronic drug interaction tools such as Medscape drug interaction checker should be available in the pharmacy section of hospitals.

Abbreviations

DDI, potential drug-drug interaction; ESKD, end stage renal disease; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease

Declarations

Ethics approval and consent to participate

Approval to conduct this study was sought from the Ethical Committee of Muhimbili University of Health and Allied Sciences. The permission to conduct the study and access to patient information was granted by MNH.

Consent for publication

Not applicable

Availability of data and material

The dataset generated and/or analyzed during this study is available from the corresponding author upon reasonable request.

Competing interests

The authors declare that they have no competing interests

Funding
Authors' contributions

WPM designed the study, data analysis and drafted the manuscript. JEM coordinated and monitored data collection. MK, WK, HM, GMB, AIM and RM participated in study design, supervision of the study, interpretation of data and manuscript development. All authors read and approved the final manuscript.

Acknowledgements

Not applicable

Authors' information (optional)

Not applicable

References

1. WHO. on Noncommunicable Diseases. 2014;

2. Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018;96(6):414-422C.

3. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. PLoS One [Internet]. 2016 Jul 6;11(7):e0158765. Available from: https://doi.org/10.1371/journal.pone.0158765

4. Hodel NC, Hamad A, Praehauser C, Mwangoka G, Kasella IM, Reither K, et al. The epidemiology of chronic kidney disease and the association with non-communicable and communicable disorders in a population of sub-Saharan Africa. PLoS One. 2018 Oct 31;13(10):e0205326.

5. Neovius M, Jacobson SH, Eriksson JK, Elinder C-G, Hylander B. Mortality in chronic kidney disease and renal replacement therapy: a population-based cohort study. BMJ Open. 2014 Feb 1;4(2):e004251.
6. Turner JM, Bauer C, Abramowitz MK, Melamed ML, Hostetter TH. Treatment of chronic kidney disease. Kidney Int [Internet]. 2012;81(4):351–62. Available from: http://dx.doi.org/10.1038/ki.2011.380

7. Zuppa F, Feudtner C. Epidemiology of Polypharmacy and Potential Drug-Drug Interactions among Pediatric Patients in Intensive Care Units of U.S. Children’s Hospitals. 2017;17(5):1-18.

8. Fasipe OJ, Akhiden PE, Nwaiwu O, Adelosoye AA. Assessment of prescribed medications and pattern of distribution for potential drug-drug interactions among chronic kidney disease patients attending the nephrology clinic of Lagos university teaching hospital in sub-saharan West Africa. Clin Pharmacol Adv Appl. 2017;9:125-32.

9. Mason N. Polypharmacy and medication-related complications in the chronic kidney disease patient. Vol. 20, Current opinion in nephrology and hypertension. 2011. 492-497 p.

10. Fasipe OJ, Akhiden PE, Beatrice O, Fasipe I, Idowu AA. The Burden of Polypharmacy and Pattern of Comorbidities among Chronic Kidney Disease Patients in Clinical Practice. 2018;

11. Masnoon N, Shakib S, Kalisch-ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. 2017;1-10.

12. Saleem A, Masood I, Khan TM. Clinical relevancy and determinants of potential drug-drug interactions in chronic kidney disease patients: results from a retrospective analysis. Integr Pharm Res Pract. 2017;Volume 6:71-7.

13. Fearon E, Chabata ST, Thompson JA, Cowan FM, Hargreaves JR. Sample Size Calculations for Population Size Estimation Studies Using Multiplier Methods With Respondent-Driven Sampling Surveys. JMIR public Heal Surveill [Internet]. 2017 Sep
14;3(3):e59–e59. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28912117

14. Pronovost P, Weast B, Schwarz M, Wyskiel RM, Prow D, Milanovich SN, et al. Medication Reconciliation: A Practical Tool to Reduce the Risk of Medication Errors. J Crit Care. 2003;18(4):201–5.

15. Al-ramahi R, Raddad AR, Rashed AO, Bsharat A, Abu-ghazaleh D, Yasin E. Evaluation of potential drug–drug interactions among Palestinian hemodialysis patients. BMC Nephrol. 2016;(August).

16. Kheshti R, Aalipour M, Namazi S. Journal of Research in Pharmacy Practice Original Article A comparison of five common drug–drug interaction software programs regarding accuracy and comprehensiveness. 2016;257–63.

17. Cardone KE, Bacchus S, Assimon MM, Pai AB, Manley HJ. Medication-related Problems in CKD. Adv Chronic Kidney Dis [Internet]. 2010 Sep 1;17(5):404-12. Available from: https://doi.org/10.1053/j.ackd.2010.06.004

18. Tesfaye WH, Wimmer BC, Peterson GM, Castelino RL, Jose M, McKercher C, et al. Effect of pharmacist-led medication review on medication appropriateness in older adults with chronic kidney disease. J Pharm Pract Res. 2019;49(5):471–6.

Tables

Table 1. Social demographic information
| Variables          | Number of patients N=198 | Percentage |
|-------------------|--------------------------|------------|
| **Gender**        |                          |            |
| Males             | 81                       | 40.9%      |
| Females           | 117                      | 59.1%      |
| **Marital status**|                          |            |
| Single            | 14                       | 7.1%       |
| Married           | 132                      | 66.7%      |
| Widowed           | 42                       | 21.2%      |
| Divorced          | 10                       |            |
| **Age (years)**   |                          |            |
| <18               | 4                        |            |
| 19-35             | 24                       | 12.1%      |
| 36-50             | 51                       | 25.8%      |
| 51-65             | 76                       | 38.4%      |
| > 65              | 43                       | 21.7%      |
| **Education level**|                         |            |
| Tertiary level    | 14                       |            |
| Secondary level   | 6                        |            |
| Primary level     | 11                       |            |
| Not recorded      | 167                      | 84.3%      |
| **Alcohol use**   |                          |            |
| Yes               | 112                      | 56.6%      |
| No                | 86                       | 43.4%      |
| **Smoking**       |                          |            |
| Yes               | 21                       | 10.6%      |
| No                | 177                      | 89.4%      |

Table 2. Chronic kidney disease stage and Co-morbidities
| Variables                           | Number of patients N=198 | Percentage |
|------------------------------------|--------------------------|------------|
| CKD stage (eGFR)\(^a\)             |                          |            |
| Stage 1 (>90 ml/min/1.73 m\(^2\))  | 0                        | 0.0%       |
| Stage 2 (60-89 ml/min/1.73 m\(^2\)) | 1                        | 0.5%       |
| Stage 3 (30-59 ml/min/1.73 m\(^2\)) | 13                       | 6.6%       |
| Stage 4 (15-29 ml/min/1.73 m\(^2\)) | 31                       | 15.7%      |
| Stage 5 (< 15 ml/min/1.73 m\(^2\)) | 153                      | 77.3%      |
| Co-morbidity                       |                          |            |
| Hypertension                       | 179                      | 90.4%      |
| Diabetes mellitus                  | 62                       | 31.3%      |
| Heart failure                      | 5                        | 2.5%       |
| HIV                                | 38                       | 19.2%      |
| Stroke                             | 9                        | 4.5%       |
| Hypertension and diabetes mellitus | 61                       | 30.8%      |
| Hypertension and HIV               | 18                       | 9.1%       |
| Hypertension, diabetes mellitus and HIV | 7            | 3.5%       |

\(^a\)The eGFR as described by Pronovost et al (14)

Table 3. Pharmacological effect of common drug-drug interaction among CKD patients
| Prescribed drugs                              | Frequency | Interaction category | Pharmacological effect of DDI                                                                 |
|----------------------------------------------|-----------|----------------------|------------------------------------------------------------------------------------------------|
| Furosemide+calcium carbonate                 | 54        | Minor                | Furosemide decreases levels of calcium carbonate                                               |
| Pantoprazole+Ferrotonc                      | 50        | Minor                | Pantoprazole decreases the level of ferrotonc                                                  |
| Bisoprolol+furosemide                       | 31        | Moderate             | Bisoprolol increases and furosemide decrease                                                    |
| Metoprolol+ furosemide                      | 27        | Moderate             | Metoprolol increases and furosemide decrease                                                    |
| Pantoprazole+ efavirenz                     | 23        | Minor                | Efavirenz increases the level of pantoprazole CYP2C19                                          |
| Clonidine+metoprolol                        | 14        | Serious              | Either increases the toxicity of the other by unspecified mechanism, can increase the risk of bradycardia |
| Furosemide+metolazone                       | 12        | Moderate             | Both decreases serum potassium                                                                  |
| Bisoprolol+clonidine                        | 11        | Serious              | Either increases toxicity of the other by unspecified mechanism, can increase the risk of bradycardia |
| Fluconazole+ pantoprazole                   | 4         | Minor                | Fluconazole increases the level of pantoprazole enzyme CYP2C19                                 |
| Ceftriazone+calcium carbonate               | 3         | Contraindicated      | Risk of potentially fatal particulate precipitation                                           |
| Carvedilol+efavirenz                        | 3         | Serious              | Efavirenz increases the level of carvedilol by CYP29/10 metabolism                              |
| Nifedipine+tolvaptan                        | 2         | Serious              | Nifedipine increases the level of tolvaptan by enzyme CYP3A4 metabolism                         |
| Ceftriazone+calcium gluconate               | 2         | Contraindicated      | Risk of potentially fatal particulate precipitation                                           |
| Aspirin + enalapril                         | 2         | Serious              | Interacts by pharmacodynamics antagonism, of vasodilating renal prostaglandins. May result in deterioration especially in elderly. |
Figures

Figure 1

Nephrological intervention among CKD patients at MNH
Figure 2

pattern of potential drug-drug interactions